MetaCap

Latigo Biotherapeutics Inc. (LTGO)

NASDAQ: LTGOHealth CareBiotechnology: Pharmaceutical PreparationsUSD

13.00-0.24 (-1.81%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LTGO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$861.89M
EPS (TTM)
-$6.07
52-week range
10.24 – 25.93
Day range
11.91 – 13.35
Volume / Avg
267.17K / 309.60K
Beta
—
Next earnings
Dec 3, 2026

52-week range

$10.24$25.93

LTGO stock today

On Nov 20, LTGO ended the session at $13.00, shedding $0.24 (1.81%), versus the S&P 500's 3.70% decline. At this level, LTGO sits near the bottom of its 52-week range of $10.24 to $25.93: 49.9% below the high, set on Aug 27, 2026 and 27.0% above the low. Latigo Biotherapeutics has posted a net loss over the last twelve months (EPS of -$6.07), so its P/E ratio is not meaningful.

The company is scheduled to report Sep/2026 results on Dec 3.

Summary generated from market data by MetaCap's automated system. Methodology

About Latigo Biotherapeutics

Company profile

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Todd N. Smith
Headquarters
Thousand Oaks, CA
Employees
66
IPO year
2026

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$52.25+301.92%

  • Strong buy 0
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $36.00High $73.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Dec 3, 2026
Last reported (Sep/2026)
Dec 3, 2026
EPS actual vs est.
$-0.55 vs —

LTGO news

All LTGO news

Latigo Biotherapeutics peers

Health Care sector
LTGO peer companies
CompanyPrice% ChgMarket capCompare
MTRIMentari Therapeutics Inc.14.70-3.57%$856.94Mvs LTGO
AKTSAktis Oncology Inc.16.15-1.52%$901.14Mvs LTGO
PHARPharming Group N.V. ADS11.54-5.10%$816.78Mvs LTGO
SVRASavara Inc.4.26-18.23%$939.86Mvs LTGO
CRVSCorvus Pharmaceuticals Inc.9.67-3.40%$815.69Mvs LTGO
MLTXMoonLake Immunotherapeutics Class A11.07+0.36%$942.13Mvs LTGO
VSTMVerastem Inc.6.33-7.73%$797.67Mvs LTGO
CYRXCryoPort Inc.19.05-2.56%$964.87Mvs LTGO

Indexes, lists and sector

Latigo Biotherapeutics stock FAQ

What is Latigo Biotherapeutics's stock price today?

LTGO last traded at $13.00 as of Nov 20, 4:00 PM EST, down 1.81% on the day. Prices are delayed at least 15 minutes.

When is Latigo Biotherapeutics's next earnings date?

Latigo Biotherapeutics is expected to report earnings on Thursday, December 3, 2026.

Who is Latigo Biotherapeutics's CEO?

Mr. Todd N. Smith is the chief executive officer of Latigo Biotherapeutics Inc., which has about 66 employees.

What is the LTGO 52-week high?

The 52-week high for LTGO is $25.93 and the 52-week low is $10.24. The stock is currently 49.9% below its high.

Compare LTGO